84 results
8-K
EX-99.1
SCYX
Scynexis Inc
28 Mar 24
SCYNEXIS Reports Full Year 2023 Financial Results
4:04pm
inventory given the potential cross-contamination of ibrexafungerp.
Research and development expense for the full year 2023 increased to $30.9 … ,
Revenue:
Product revenue, net
License agreement revenue
Total revenue
Operating expenses:
Cost of product revenue
Research and development
Selling
424B5
SCYX
Scynexis Inc
28 Nov 23
Prospectus supplement for primary offering
4:05pm
offered by us hereunder, if any, for working capital and general corporate purposes, including research and development expenses, clinical trials … corporate purposes, including research and development expenses, clinical trials and capital expenditures.
The amounts and timing of our use
424B5
dyx1hik vf
28 Nov 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
liqme3tq2e3e96xragz
9 Nov 22
SCYNEXIS Reports Third Quarter 2022 Financial Results
7:16am
8-K
kfp20 k02j
20 Oct 22
Termination of a Material Definitive Agreement
5:21pm